Fig. 3

Administration of hAECs on day 8, 10, and 12 suppresses the development of RR-EAE. a Clinical scores of NOD/Lt mice injected i.p. with one or five million hAECs or PBS on day 8, 10, and 12 (indicated by arrows) (n = 7, *P < 0.05 compared to PBS). Clinical scores (b) and cumulative disease score (c) of NOD/Lt mice injected i.p. with 0.1, 0.25, or 0.5 million hAECs or PBS on day 1 and 3 (indicated by arrows) (n = 6–7, **P < 0.01 compared to PBS). Representative spinal cord sections from PBS control mice stained with H&E (d), LFB (f), or Bielschowsky silver stain (h) or mice that received five million hAECs stained with H&E (e), LFB (g), or Bielschowsky silver stain (i) to assess inflammation, demyelination, and axonal damage, respectively. Magnification × 100. IBA-1+ immunoreactivity in the grey matter of spinal cord sections from PBS controls (j) or mice that received five million hAECs (k). Magnification × 400. (l) Total number of IBA-1+ cells/mm² in different regions of the CNS in PBS controls and hAEC-treated mice (*P < 0.05 compared to PBS)